WebApr 11, 2024 · DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced an agreement with a Blues ...
DermTech Management to Participate at the Lake Street 2024 …
WebAt the Annual Meeting, one (1) person will be elected to our board of directors. In addition, we will ask our stockholders to approve a proposed amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the aggregate number of shares of common stock authorized to be issued by the Company, to approve an amendment to … WebApr 9, 2024 · 5 Wall Street research analysts have issued 1-year price objectives for DermTech's stock. Their DMTK share price forecasts range from $5.00 to $23.00. On … drug treatment for hodgkin lymphoma
Breaking News: DMTK latest news. - The Fly
WebApr 6, 2024 · Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools. Identify stocks that meet your criteria using seven unique stock screeners. WebDMTK Stock 12 Months Forecast. $6.50. (100.00% Upside) Based on 2 Wall Street analysts offering 12 month price targets for DermTech in the last 3 months. The average … WebApr 12, 2024 · DermTech Inc does not have a meaningful P/E due to negative earnings over the last 12 trailing months. DermTech Inc’s trailing 12-month revenue is $14.5 million with a -803.7% profit margin. Year-over-year quarterly sales growth most recently was -6.3%. Analysts expect adjusted earnings to reach $-3.503 per share for the current fiscal year. drug treatment for h pylori infection